Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease (359 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2008 Apr; 31(4): 352-359.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 1.888, 5-year impact factor: 2.131
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-44849143348&partnerID=40&md5=92a15ed020482a1a4499af753b5664c6
Keywords: [111in-Dtpa0], Mibg Scintigraphy, Neuroendocrine Tumors, Octreotide Scintigraphy, Pheochromocytoma, Von Hippel-Lindau Disease, (3 Iodobenzyl)guanidine I 131, 10 Tetraazacyclododecane 1, 10 Tetraacetic Acid Octreotide[3 Tyrosine] Y 90, C Peptide, Catecholamine, Gastrin, Insulin, Iopromide, Lysine, Neuron Specific Enolase, Pentetreotide In 111, Radiopharmaceutical Agent, Somatostatin Derivative, Somatostatin Receptor, 111in Octreotide, Dtpa(0), 111in-Octreotide, Diagnostic Agent, Drug Derivative, Indium, Pentetic Acid, Adrenalectomy, Adult, Angioma, Article, Blood Toxicity, Case Report, Contrast Enhancement, Diagnostic Value, Female, Follow Up, Genetic Association, Genetic Counseling, Human, Human Tissue, Hypertension, Immunohistochemistry, In Vitro Study, In Vivo Study, Liver Metastasis, Multiple Cycle Treatment, Pancreas Tumor, Pancreaticoduodenectomy, Paraganglioma, Pedigree Analysis, Protein Expression, Retina Tumor, Scintiscanning, Spiral Computer Assisted Tomography, Tachycardia, Treatment Refusal, Tumor Volume, Von Hippel Lindau Disease, Whole Body Scintiscanning, Computer Assisted Emission Tomography, Methodology, Indium Radioisotopes, Emission-Computed, (3 Iodobenzyl) Guanidine I 131, 10 Tetraacetic Acid Octreotide [3 Tyrosine] Y 90, Dtpa (0),
Affiliations:
*** IBB - CNR ***
Department of Clinical and Molecular Endocrinology and Oncology, Federico II University of Naples, Via S. Pansini 5, 80131 Naples, Italy
Department of Biomorphological and Functional Sciences, Federico II University of Naples, Naples, Italy
Department of Endocrinological and Metabolic Sciences (DISEM), University of Genoa, Genoa, Italy
Department of Nuclear Medicine, European Institute of Oncology, Milan, Italy
References:
Maher, E.R., Iselius, L., Yates, J.R., Von Hippel-Lindau disease: A genetic study (1991) J Med Genet, 28, pp. 443-44
Latif, F., Tory, K., Gnarra, J., Identification of the von Hippel-Lindau disease tumor suppressor gene (1993) Science, 260, pp. 1317-1320
Ong, K.R., Woodward, E.R., Killick, P., Lim, C., Macdonald, F., Maher, E.R., Genotype-phenotype correlations in von Hippel-Lindau disease (2007) Hum Mutat, 28, pp. 143-149
Weirich, G., Klein, B., Wohl, T., Engelhardt, D., Brauch, H., VHL2C phenotype in a german von Hippel-Lindau family with concurrent VHL gemline mutations P81S and L188V (2002) J Clin Endocrinol Metab, 87, pp. 5241-5246
Choyke, P.L., Glenn, G.M., Walther, M.M., Patronas, N.J., Linehan, W.M., Zbar, B., von Hippel-Lindau disease: Genetic, clinical and imaging features (1995) Radiology, 194, pp. 629-642
Choyke, P.L., Filling-Katz, M.R., Shawker, T.H., von Hippel-Lindau disease: Radiologic screening for visceral manifestations (1990) Radiology, 174, pp. 815-820
Janson, E.T., Oberg, K., Neuroendocrine tumors - somatostatin receptor expression and somatostatin analog treatment (2003) Cancer Chemother Biol Response Modif, 21, pp. 535-546
Duet, M., Sauvaget, E., Pételle, B., Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck (2003) J Nucl Med, 44, pp. 1767-1774
Kaltsas, G., Rockall, A., Papadogias, D., Reznek, R., Grossman, A.B., Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours (2004) Eur J Endocrinol, 151, pp. 15-27
Duet, M., Guichard, J.P., Rizzo, N., Boudiaf, M., Herman, P., Tran, Ba Huy, P., Are somatostatin analogs therapeutic alternatives in the management of head and neck paragangliomas? (2005) Laryngoscope, 115, pp. 1381-1384
Shojamanesh, H., Gibril, F., Louie, A., Prospective study of the antitumor efficacy of longterm octreotide treatment in patients with progressive metastatic gastrinoma (2002) Cancer, 94, pp. 331-343
Bodei, L., Cremonesi, M., Grana, C., Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours (2004) Eur J Nucl Med Mol Imaging, 31, pp. 1038-1046
Waldherr, C., Pless, M., Maecke, H.R., Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC (2002) J Nucl Med, 43, pp. 610-616
Libutti, S.K., Choyke, P.L., Bartlett, D.L., Pancreatic neuroendocrine tumors associated with von Hippel Lindau diseases: Diagnostic and management recommendations (1998) Surgery, 124, pp. 1153-1159
Ferone, D., van Hagen, M.P., Kwekkeboom, D.J., Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro (2000) J Clin Endocrinol Metab, 85, pp. 1719-1726
Heppeler, A., Froidevaux, S., Mäcke, H.R., Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy (1999) Chem Eur J, 5, pp. 1016-1023
Chinol, M., Bodei, L., Cremonesi, M., Paganelli, G., Receptor-mediated radiotherapy with 90YDOTA-D-Phe1-Tyr3-octreotide: The experience of the European Institute of Oncology group (2002) Semin Nucl Med, 32, pp. 141-147
Miller, A.B., Hoogstraten, B., Staquet, M., Winkler, A., Reporting results of cancer treatment (1981) Cancer, 47, pp. 207-214
Camera, L., Biondi, B., Daniele, S., Screening in von Hippel-Lindau disease: Concurrent pheochromocytomas, paragangliomas and spinal hemangioblastomas revealed by helical-CT, MIBG scintigraphy and MRI in an asymptomatic patient (2003) European Journal of Radiology Extra, 48, pp. 8-13
Opocher, G., Conton, P., Schiavi, F., Macino, B., Mantero, F., Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1 (2005) Fam Cancer, 4, pp. 13-16
Lenders, J.W., Eisenhofer, G., Mannelli, M., Pacak, K., Phaeochromocytoma (2005) Lancet, 366, pp. 665-675
Neumann, H.P., Bausch, B., McWhinney, S.R., Germ-line mutations in nonsyndromic pheochromocytoma (2002) N Engl J Med, 346, pp. 1459-1466
Hoefnagel, C.A., Metaiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumours (1994) Eur J Nucl Med, 25, pp. 561-581
Tenenbaum, F., Lumbroso, J., Schlumberger, M., Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma (1995) J Nucl Med, 36, pp. 1-6
van der Harst, E., de Herder, W., Bruining, H.A., 1231-Metaiodobenzylguanidine and 111In-Octreotide uptake in benign and malignant pheochromocytomas (2001) J Clin Endocrinol Metab, 86, pp. 685-693
Kwekkeboom, D.J., van Urk, H., Pauw, B.K., Octreotide scintigraphy for the detection of paragangliomas (1993) J Nucl Med, 34, pp. 873-878
Schmidt, M., Fischer, E., Dietlein, M., Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas (2002) Eur J Nucl Med Mol Imaging, 29, pp. 1571-1580
Hofland, L.J., Lamberts, S.W., The pathophysiological consequences of somatostatin receptor internalization and resistance (2003) Endocr Rev, 24, pp. 28-47
Mukhopadhyay, B., Sahdev, A., Monson, J.P., Besser, G.M., Reznek, R.H., Chew, S.L., Pancreatic lesions in von Hippel-Lindau disease (2002) Clin Endocrinol (Oxf), 57, pp. 603-608
Lamberts, S.W., Hofland, L.J., van Koetsveld, P.M., Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: Consequences with regard to diagnosis, localisation and therapy (1990) J Clin Endocrinol Metab, 71, pp. 566-574
Krenning, E.P., Kwekkeboom, D.J., Bakker, W.H., Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients (1993) Eur J Nucl Med, 20, pp. 716-731
Chiti, A., Fanti, S., Savelli, G., Romeo, A., Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours (1998) Eur J Nucl Med, 25, pp. 1396-1403
Reubi, J.C., Waser, B., Laissue, J.A., Gebbers, J.O., Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumours: In vitro identification (1992) Cancer Res, 56, pp. 1922-1931
Reubi, J.C., Kvols, L., Somatostatin receptors in human renal cell carcinomas (1992) Cancer Res, 52, pp. 6074-6078
Eriksson, B., Oberg, K., Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: Future outlook (1999) Ann Oncol, 10 (SUPPL. 2), pp. S31-S38
Kvols, L.K., Moertel, C.G., O'Connell, M.J., Schutt, A.J., Rubin, J., Hahn, R.G., Treatment of malignant carcinoid syndrome, evaluation of a long-acting somatostatin analogue (1986) N Engl J Med, 315, pp. 663-666
Maher, E. R., Iselius, L., Yates, J. R., Von Hippel-Lindau disease: A genetic study (1991) J Med Genet, 28, pp. 443-44
Ong, K. R., Woodward, E. R., Killick, P., Lim, C., Macdonald, F., Maher, E. R., Genotype-phenotype correlations in von Hippel-Lindau disease (2007) Hum Mutat, 28, pp. 143-149
Choyke, P. L., Glenn, G. M., Walther, M. M., Patronas, N. J., Linehan, W. M., Zbar, B., von Hippel-Lindau disease: Genetic, clinical and imaging features (1995) Radiology, 194, pp. 629-642
Choyke, P. L., Filling-Katz, M. R., Shawker, T. H., von Hippel-Lindau disease: Radiologic screening for visceral manifestations (1990) Radiology, 174, pp. 815-820
Janson, E. T., Oberg, K., Neuroendocrine tumors - somatostatin receptor expression and somatostatin analog treatment (2003) Cancer Chemother Biol Response Modif, 21, pp. 535-546
Libutti, S. K., Choyke, P. L., Bartlett, D. L., Pancreatic neuroendocrine tumors associated with von Hippel Lindau diseases: Diagnostic and management recommendations (1998) Surgery, 124, pp. 1153-1159
Miller, A. B., Hoogstraten, B., Staquet, M., Winkler, A., Reporting results of cancer treatment (1981) Cancer, 47, pp. 207-214
Lenders, J. W., Eisenhofer, G., Mannelli, M., Pacak, K., Phaeochromocytoma (2005) Lancet, 366, pp. 665-675
Neumann, H. P., Bausch, B., McWhinney, S. R., Germ-line mutations in nonsyndromic pheochromocytoma (2002) N Engl J Med, 346, pp. 1459-1466
Hoefnagel, C. A., Metaiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumours (1994) Eur J Nucl Med, 25, pp. 561-581
Kwekkeboom, D. J., van Urk, H., Pauw, B. K., Octreotide scintigraphy for the detection of paragangliomas (1993) J Nucl Med, 34, pp. 873-878
Hofland, L. J., Lamberts, S. W., The pathophysiological consequences of somatostatin receptor internalization and resistance (2003) Endocr Rev, 24, pp. 28-47
Lamberts, S. W., Hofland, L. J., van Koetsveld, P. M., Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: Consequences with regard to diagnosis, localisation and therapy (1990) J Clin Endocrinol Metab, 71, pp. 566-574
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1] - and [123I-Tyr3] -octreotide: The Rotterdam experience with more than 1000 patients (1993) Eur J Nucl Med, 20, pp. 716-731
Reubi, J. C., Waser, B., Laissue, J. A., Gebbers, J. O., Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumours: In vitro identification (1992) Cancer Res, 56, pp. 1922-1931
Reubi, J. C., Kvols, L., Somatostatin receptors in human renal cell carcinomas (1992) Cancer Res, 52, pp. 6074-6078
Kvols, L. K., Moertel, C. G., O'Connell, M. J., Schutt, A. J., Rubin, J., Hahn, R. G., Treatment of malignant carcinoid syndrome, evaluation of a long-acting somatostatin analogue (1986) N Engl J Med, 315, pp. 663-666
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2008 Apr; 31(4): 352-359.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 1.888, 5-year impact factor: 2.131
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-44849143348&partnerID=40&md5=92a15ed020482a1a4499af753b5664c6
Keywords: [111in-Dtpa0], Mibg Scintigraphy, Neuroendocrine Tumors, Octreotide Scintigraphy, Pheochromocytoma, Von Hippel-Lindau Disease, (3 Iodobenzyl)guanidine I 131, 10 Tetraazacyclododecane 1, 10 Tetraacetic Acid Octreotide[3 Tyrosine] Y 90, C Peptide, Catecholamine, Gastrin, Insulin, Iopromide, Lysine, Neuron Specific Enolase, Pentetreotide In 111, Radiopharmaceutical Agent, Somatostatin Derivative, Somatostatin Receptor, 111in Octreotide, Dtpa(0), 111in-Octreotide, Diagnostic Agent, Drug Derivative, Indium, Pentetic Acid, Adrenalectomy, Adult, Angioma, Article, Blood Toxicity, Case Report, Contrast Enhancement, Diagnostic Value, Female, Follow Up, Genetic Association, Genetic Counseling, Human, Human Tissue, Hypertension, Immunohistochemistry, In Vitro Study, In Vivo Study, Liver Metastasis, Multiple Cycle Treatment, Pancreas Tumor, Pancreaticoduodenectomy, Paraganglioma, Pedigree Analysis, Protein Expression, Retina Tumor, Scintiscanning, Spiral Computer Assisted Tomography, Tachycardia, Treatment Refusal, Tumor Volume, Von Hippel Lindau Disease, Whole Body Scintiscanning, Computer Assisted Emission Tomography, Methodology, Indium Radioisotopes, Emission-Computed, (3 Iodobenzyl) Guanidine I 131, 10 Tetraacetic Acid Octreotide [3 Tyrosine] Y 90, Dtpa (0),
Affiliations:
*** IBB - CNR ***
Department of Clinical and Molecular Endocrinology and Oncology, Federico II University of Naples, Via S. Pansini 5, 80131 Naples, Italy
Department of Biomorphological and Functional Sciences, Federico II University of Naples, Naples, Italy
Department of Endocrinological and Metabolic Sciences (DISEM), University of Genoa, Genoa, Italy
Department of Nuclear Medicine, European Institute of Oncology, Milan, Italy
References:
Maher, E.R., Iselius, L., Yates, J.R., Von Hippel-Lindau disease: A genetic study (1991) J Med Genet, 28, pp. 443-44
Latif, F., Tory, K., Gnarra, J., Identification of the von Hippel-Lindau disease tumor suppressor gene (1993) Science, 260, pp. 1317-1320
Ong, K.R., Woodward, E.R., Killick, P., Lim, C., Macdonald, F., Maher, E.R., Genotype-phenotype correlations in von Hippel-Lindau disease (2007) Hum Mutat, 28, pp. 143-149
Weirich, G., Klein, B., Wohl, T., Engelhardt, D., Brauch, H., VHL2C phenotype in a german von Hippel-Lindau family with concurrent VHL gemline mutations P81S and L188V (2002) J Clin Endocrinol Metab, 87, pp. 5241-5246
Choyke, P.L., Glenn, G.M., Walther, M.M., Patronas, N.J., Linehan, W.M., Zbar, B., von Hippel-Lindau disease: Genetic, clinical and imaging features (1995) Radiology, 194, pp. 629-642
Choyke, P.L., Filling-Katz, M.R., Shawker, T.H., von Hippel-Lindau disease: Radiologic screening for visceral manifestations (1990) Radiology, 174, pp. 815-820
Janson, E.T., Oberg, K., Neuroendocrine tumors - somatostatin receptor expression and somatostatin analog treatment (2003) Cancer Chemother Biol Response Modif, 21, pp. 535-546
Duet, M., Sauvaget, E., Pételle, B., Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck (2003) J Nucl Med, 44, pp. 1767-1774
Kaltsas, G., Rockall, A., Papadogias, D., Reznek, R., Grossman, A.B., Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours (2004) Eur J Endocrinol, 151, pp. 15-27
Duet, M., Guichard, J.P., Rizzo, N., Boudiaf, M., Herman, P., Tran, Ba Huy, P., Are somatostatin analogs therapeutic alternatives in the management of head and neck paragangliomas? (2005) Laryngoscope, 115, pp. 1381-1384
Shojamanesh, H., Gibril, F., Louie, A., Prospective study of the antitumor efficacy of longterm octreotide treatment in patients with progressive metastatic gastrinoma (2002) Cancer, 94, pp. 331-343
Bodei, L., Cremonesi, M., Grana, C., Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours (2004) Eur J Nucl Med Mol Imaging, 31, pp. 1038-1046
Waldherr, C., Pless, M., Maecke, H.R., Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC (2002) J Nucl Med, 43, pp. 610-616
Libutti, S.K., Choyke, P.L., Bartlett, D.L., Pancreatic neuroendocrine tumors associated with von Hippel Lindau diseases: Diagnostic and management recommendations (1998) Surgery, 124, pp. 1153-1159
Ferone, D., van Hagen, M.P., Kwekkeboom, D.J., Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro (2000) J Clin Endocrinol Metab, 85, pp. 1719-1726
Heppeler, A., Froidevaux, S., Mäcke, H.R., Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy (1999) Chem Eur J, 5, pp. 1016-1023
Chinol, M., Bodei, L., Cremonesi, M., Paganelli, G., Receptor-mediated radiotherapy with 90YDOTA-D-Phe1-Tyr3-octreotide: The experience of the European Institute of Oncology group (2002) Semin Nucl Med, 32, pp. 141-147
Miller, A.B., Hoogstraten, B., Staquet, M., Winkler, A., Reporting results of cancer treatment (1981) Cancer, 47, pp. 207-214
Camera, L., Biondi, B., Daniele, S., Screening in von Hippel-Lindau disease: Concurrent pheochromocytomas, paragangliomas and spinal hemangioblastomas revealed by helical-CT, MIBG scintigraphy and MRI in an asymptomatic patient (2003) European Journal of Radiology Extra, 48, pp. 8-13
Opocher, G., Conton, P., Schiavi, F., Macino, B., Mantero, F., Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1 (2005) Fam Cancer, 4, pp. 13-16
Lenders, J.W., Eisenhofer, G., Mannelli, M., Pacak, K., Phaeochromocytoma (2005) Lancet, 366, pp. 665-675
Neumann, H.P., Bausch, B., McWhinney, S.R., Germ-line mutations in nonsyndromic pheochromocytoma (2002) N Engl J Med, 346, pp. 1459-1466
Hoefnagel, C.A., Metaiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumours (1994) Eur J Nucl Med, 25, pp. 561-581
Tenenbaum, F., Lumbroso, J., Schlumberger, M., Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma (1995) J Nucl Med, 36, pp. 1-6
van der Harst, E., de Herder, W., Bruining, H.A., 1231-Metaiodobenzylguanidine and 111In-Octreotide uptake in benign and malignant pheochromocytomas (2001) J Clin Endocrinol Metab, 86, pp. 685-693
Kwekkeboom, D.J., van Urk, H., Pauw, B.K., Octreotide scintigraphy for the detection of paragangliomas (1993) J Nucl Med, 34, pp. 873-878
Schmidt, M., Fischer, E., Dietlein, M., Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas (2002) Eur J Nucl Med Mol Imaging, 29, pp. 1571-1580
Hofland, L.J., Lamberts, S.W., The pathophysiological consequences of somatostatin receptor internalization and resistance (2003) Endocr Rev, 24, pp. 28-47
Mukhopadhyay, B., Sahdev, A., Monson, J.P., Besser, G.M., Reznek, R.H., Chew, S.L., Pancreatic lesions in von Hippel-Lindau disease (2002) Clin Endocrinol (Oxf), 57, pp. 603-608
Lamberts, S.W., Hofland, L.J., van Koetsveld, P.M., Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: Consequences with regard to diagnosis, localisation and therapy (1990) J Clin Endocrinol Metab, 71, pp. 566-574
Krenning, E.P., Kwekkeboom, D.J., Bakker, W.H., Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients (1993) Eur J Nucl Med, 20, pp. 716-731
Chiti, A., Fanti, S., Savelli, G., Romeo, A., Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours (1998) Eur J Nucl Med, 25, pp. 1396-1403
Reubi, J.C., Waser, B., Laissue, J.A., Gebbers, J.O., Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumours: In vitro identification (1992) Cancer Res, 56, pp. 1922-1931
Reubi, J.C., Kvols, L., Somatostatin receptors in human renal cell carcinomas (1992) Cancer Res, 52, pp. 6074-6078
Eriksson, B., Oberg, K., Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: Future outlook (1999) Ann Oncol, 10 (SUPPL. 2), pp. S31-S38
Kvols, L.K., Moertel, C.G., O'Connell, M.J., Schutt, A.J., Rubin, J., Hahn, R.G., Treatment of malignant carcinoid syndrome, evaluation of a long-acting somatostatin analogue (1986) N Engl J Med, 315, pp. 663-666
Maher, E. R., Iselius, L., Yates, J. R., Von Hippel-Lindau disease: A genetic study (1991) J Med Genet, 28, pp. 443-44
Ong, K. R., Woodward, E. R., Killick, P., Lim, C., Macdonald, F., Maher, E. R., Genotype-phenotype correlations in von Hippel-Lindau disease (2007) Hum Mutat, 28, pp. 143-149
Choyke, P. L., Glenn, G. M., Walther, M. M., Patronas, N. J., Linehan, W. M., Zbar, B., von Hippel-Lindau disease: Genetic, clinical and imaging features (1995) Radiology, 194, pp. 629-642
Choyke, P. L., Filling-Katz, M. R., Shawker, T. H., von Hippel-Lindau disease: Radiologic screening for visceral manifestations (1990) Radiology, 174, pp. 815-820
Janson, E. T., Oberg, K., Neuroendocrine tumors - somatostatin receptor expression and somatostatin analog treatment (2003) Cancer Chemother Biol Response Modif, 21, pp. 535-546
Libutti, S. K., Choyke, P. L., Bartlett, D. L., Pancreatic neuroendocrine tumors associated with von Hippel Lindau diseases: Diagnostic and management recommendations (1998) Surgery, 124, pp. 1153-1159
Miller, A. B., Hoogstraten, B., Staquet, M., Winkler, A., Reporting results of cancer treatment (1981) Cancer, 47, pp. 207-214
Lenders, J. W., Eisenhofer, G., Mannelli, M., Pacak, K., Phaeochromocytoma (2005) Lancet, 366, pp. 665-675
Neumann, H. P., Bausch, B., McWhinney, S. R., Germ-line mutations in nonsyndromic pheochromocytoma (2002) N Engl J Med, 346, pp. 1459-1466
Hoefnagel, C. A., Metaiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumours (1994) Eur J Nucl Med, 25, pp. 561-581
Kwekkeboom, D. J., van Urk, H., Pauw, B. K., Octreotide scintigraphy for the detection of paragangliomas (1993) J Nucl Med, 34, pp. 873-878
Hofland, L. J., Lamberts, S. W., The pathophysiological consequences of somatostatin receptor internalization and resistance (2003) Endocr Rev, 24, pp. 28-47
Lamberts, S. W., Hofland, L. J., van Koetsveld, P. M., Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: Consequences with regard to diagnosis, localisation and therapy (1990) J Clin Endocrinol Metab, 71, pp. 566-574
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1] - and [123I-Tyr3] -octreotide: The Rotterdam experience with more than 1000 patients (1993) Eur J Nucl Med, 20, pp. 716-731
Reubi, J. C., Waser, B., Laissue, J. A., Gebbers, J. O., Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumours: In vitro identification (1992) Cancer Res, 56, pp. 1922-1931
Reubi, J. C., Kvols, L., Somatostatin receptors in human renal cell carcinomas (1992) Cancer Res, 52, pp. 6074-6078
Kvols, L. K., Moertel, C. G., O'Connell, M. J., Schutt, A. J., Rubin, J., Hahn, R. G., Treatment of malignant carcinoid syndrome, evaluation of a long-acting somatostatin analogue (1986) N Engl J Med, 315, pp. 663-666
Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease
The identification of patients with von Hippel-Lindau (VHL) disease dictates accurate genetic counseling of family members, whereas screening for early detection of visceral and neurological involvement is usually performed by a combination of radiological and nuclear medicine techniques such as ultrasonography or contrast-enhanced computed tomography of the upper abdomen, magnetic resonance imaging of the central nervous system and 131I-metaiodobenzylguanidine-scintigraphy. The role of 111-indium-diethylenetriaminepentaacetic acid [111In-DTPA0] octreotide scintigraphy in this clinical context has never been investigated. Here, we report imaging findings in a VHL patient and in 3 consecutive family members undergoing clinical and radiological screening that included [111In-DTPA0] octreoticle scintigraphy in addition to the above-mentioned procedures. Somatostatin receptor expression was investigated in vitro by immunohistochemistry in pancreatic tumor sections. On the basis of in vivo and in vitro findings, octreotide long-acting release treatment followed by 90Y-1, 4, 7, 10-Tetraazacyclododecane-N, N', N'', N'''-tetraacetic acid (DOTA0) -Tyr3-octreotide led to a lack of progression in this patient although this result is a possibility which needs to be proved by further investigation and longer follow-up. The results of this study suggest that [111In-DTPA0] octreotide scintigraphy may be helpful in the routine work-up of VHL patients for diagnostic and therapeutic purposes. 2008, Editrice Kurtis
The identification of patients with von Hippel-Lindau (VHL) disease dictates accurate genetic counseling of family members, whereas screening for early detection of visceral and neurological involvement is usually performed by a combination of radiological and nuclear medicine techniques such as ultrasonography or contrast-enhanced computed tomography of the upper abdomen, magnetic resonance imaging of the central nervous system and 131I-metaiodobenzylguanidine-scintigraphy. The role of 111-indium-diethylenetriaminepentaacetic acid [111In-DTPA0] octreotide scintigraphy in this clinical context has never been investigated. Here, we report imaging findings in a VHL patient and in 3 consecutive family members undergoing clinical and radiological screening that included [111In-DTPA0] octreoticle scintigraphy in addition to the above-mentioned procedures. Somatostatin receptor expression was investigated in vitro by immunohistochemistry in pancreatic tumor sections. On the basis of in vivo and in vitro findings, octreotide long-acting release treatment followed by 90Y-1, 4, 7, 10-Tetraazacyclododecane-N, N', N'', N'''-tetraacetic acid (DOTA0) -Tyr3-octreotide led to a lack of progression in this patient although this result is a possibility which needs to be proved by further investigation and longer follow-up. The results of this study suggest that [111In-DTPA0] octreotide scintigraphy may be helpful in the routine work-up of VHL patients for diagnostic and therapeutic purposes. 2008, Editrice Kurtis
Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease
| ▼ Clinical Oncology |
Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease
Other filter: ([btitle,keywords] "[111in-Dtpa0]" OR [b ...
Verde F, Galatola R, Romeo V, Perillo T, Liuzzi R, Camera L, Klain M, Modica R, Faggiano A, Napolitano V, Colao A, Brunetti A, Maurea S
* Pancreatic Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: Diagnostic Value of Different MRI Sequences (19 views)
Neuroendocrinology (ISSN: 0028-3835linking), 2021; 111(7): 696-704.
Impact Factor: 4.271
View Export to BibTeX Export to EndNote
Dell'Aversana S, Coppola M, Balestrieri U, Mainenti PP, Pascale C, Imbriaco M, Chianca V, Romeo V, Pellegrino T, Mainolfi C, Maurea S
* Integrated Imaging Characterization of Adrenal Adenoma: False-Positive Metaiodobenzylguanidine (MIBG) Findings of Adrenal Scintigraphy (167 views)
Pol J Radiol (ISSN: 1733-134xlinking), 2017 Aug 4; 82: 422-425.
Impact Factor: 0.567
View Export to BibTeX Export to EndNote
Lastoria S, Marciello F, Faggiano A, Aloj L, Caraco C, Aurilio M, D'Ambrosio L, Di Gennaro F, Ramundo V, Camera L, De LucaL, Fonti R, Napolitano V, Colao A
* Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1) (259 views)
Endocrine (ISSN: 1355-008x), 2016 Jun; 52(3): 488-494.
Impact Factor: 3.131
View Export to BibTeX Export to EndNote
Marcucci G, Cianferotti L, Beck-Peccoz P, Capezzone M, Cetani F, Colao A, Davì MV, Degli Uberti E, Del Prato S, Elisei R, Faggiano A, Ferone D, Foresta C, Fugazzola L, Ghigo E, Giacchetti G, Giorgino F, Lenzi A, Malandrino P, Mannelli M, Marcocci C, Masi L, Pacini F, Opocher G, Radicioni A, Tonacchera M, Vigneri R, Zatelli MC, Brandi ML
* Rare diseases in clinical endocrinology: A taxonomic classification system (778 views)
J Endocrinol Invest (ISSN: 1720-8386, 0391-4097, 1720-8386electronic), 2015; 38(2): 193-259.
Impact Factor: 1.994
View Export to BibTeX Export to EndNote
Maurea S, Fiumara G, Pellegrino T, Zampella E, Assante R, Mainenti PP, Cuocolo A
* MIBG molecular imaging for evaluating response to chemotherapy in patients with malignant pheochromocytoma: preliminary results (252 views)
Cancer Imaging (ISSN: 1470-7330, 1470-7330electronic, 1470-7330linking), 2013 Apr 15; 13: 155-161.
Impact Factor: 1.286
View Export to BibTeX Export to EndNote
De Luca S, Fonti R, Palmieri G, Federico P, Del Prete G, Pacelli R, Pace L, De Placido S, Salvatore M, Del Vecchio S
* Combined Imaging With 18f-Fdg-Pet/Ct And 111in-Labeled Octreotide Spect For Evaluation Of Thymic Epithelial Tumors (350 views)
Clin Nucl Med (ISSN: 1536-0229, 0363-3976, 0363-9762), 2013; 38(5): 354-358.
Impact Factor: 2.857
View Export to BibTeX Export to EndNote
Maurea S, Cuocolo A, Imbriaco M, Pellegrino T, Fusari M, Cuocolo R, Liuzzi R, Salvatore M
* Imaging characterization of benign and malignant pheochromocytoma or paraganglioma: comparison between MIBG uptake and MR signal intensity ratio (372 views)
Ann Nucl Med (ISSN: 1864-6433, 0914-7187, 1864-6433electronic), 2012 Oct; 26(8): 670-675.
Impact Factor: 1.41
View Export to BibTeX Export to EndNote
Faggiano A, Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Lombardi G, Colao A
* Long-Acting Somatostatin Analogues are Highly Effective in Patients with Early Stage MEN-1-Related Well-Differentiated Neuroendocrine Tumors (223 views)
Neuroendocrinology (ISSN: 0028-3835, 0028-3835linking), 2012; 96: N/D-N/D.
Impact Factor: 3.537
View Export to BibTeX Export to EndNote
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (479 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
View Export to BibTeX Export to EndNote
Maurea S, Soricelli A, Salvatore M
* Characterization of hypersecreting or non-hypersecreting adrenal adenomas: Comparison between iodine-131 nor-cholesterol scintigraphy and magnetic resonance imaging (315 views) (PDF 247 views)
Curr Radiopharm (ISSN: 1874-4710, 1874-4729), 2009; 2(1): 56-62.
Impact Factor: 0.643
View Export to BibTeX Export to EndNote
Maurea S, Imbriaco M, D'Angelillo M, Mollica C, Camera L, Salvatore M
* Diagnostic accuracy of chemical-shift MR imaging to differentiate between adrenal adenomas and non adenoma adrenal lesions (327 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 2006 Sep; 111(5): 674-686.
Impact Factor: 1.368
View Export to BibTeX Export to EndNote
Aloj L, Caracò C, Panico M, Zannetti A, Del Vecchio S, Tesauro D, De Luca S, Arra C, Pedone C, Morelli G, Salvatore M
* In vitro and in vivo evaluation of In-111-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging (587 views)
J Nucl Med (ISSN: 1535-5667, 0161-5505, 1535-5667electronic), 2004 Mar; 45(3): 485-494.
Impact Factor: 5.362
View Export to BibTeX Export to EndNote
Aloj L, Panico M, Caraco C, Del Vecchio S, Arra C, Affuso A, Accardo A, Mansi R, Tesauro D, De Luca S, Pedone C, Visentin R, Mazzi U, Morelli G, Salvatore M
* In vitro and in vivo characterization of Indium-111 and Technetium-99m labeled CCK-8 derivatives for CCK-B receptor imaging (519 views)
Cancer Biotherapy And Radiopharmaceuticals (ISSN: 1084-9785, 1084-4978), 2004 Feb; 19(1): 93-98.
Impact Factor: 1.091
View Export to BibTeX Export to EndNote
Maurea S, Caracò C, Klain M, Mainolfi C, Salvatore M
* Imaging characterization of non-hypersecreting adrenal masses. Comparison between MR and radionuclide techniques (350 views) (PDF 247 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2004; 48(3): 188-197.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
Camera L, Del Vecchio S, Quarantelli M, Ibello F, Pellegrino T, Salvatore M
* Radiolabeled somatostatin analogs in the diagnosis and staging of neuroendocrine tumors (329 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2003; 26(8Suppl): 60-62.
Impact Factor: 1.621
View Export to BibTeX Export to EndNote
Camera L, Biondi B, Daniele S, Pace L, Di Nuzzo L, Tortora F, Pulcrano M, Pagano L, Briganti F, Lombardi G, Salvatore M
* Screening in von Hippel-Lindau disease: Concurrent pheochromocytomas, paragangliomas and spinal hemangioblastomas revealed by helical-CT, MIBG scintigraphy and MRI in an asymptomatic patient (307 views)
Eur J Radiol Extra, 2003; 48(1): 8-13.
Impact Factor: 2.16
View Export to BibTeX Export to EndNote
Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M
* The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses (269 views) (PDF 247 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2001 Jun; 42(6): 884-892.
Impact Factor: 4.51
View Export to BibTeX Export to EndNote
Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G
The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas (387 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 1999 Mar; 22(3): 176-183.
Impact Factor: 0.957
View Export to BibTeX Export to EndNote
Lastoria S, Vergara E, Palmieri G, Acampa W, Varrella P, Caracò C, Bianco RA, Muto P, Salvatore M
In vivo detection of malignant thymic masses by indium-111-DTPA-D- Phe1-octreotide scintigraphy (428 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1998 Apr; 39(4): 634-639.
Impact Factor: 3.064
View Export to BibTeX Export to EndNote
Maurea S, Lastoria S, Caracò C, Klain M, Varrella P, Acampa W, Muto P, Salvatore M
The role of radiolabeled somatostatin analogs in adrenal imaging (358 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1996 Sep; 23(6): 677-680.
Impact Factor: 1.042
View Export to BibTeX Export to EndNote
Maurea S, Cuocolo A, Reynolds JC, Neumann RD, Salvatore M
Diagnostic imaging in patients with paragangliomas. Computer tomography, magnetic resonance and MIBG scintigraphy comparison (309 views)
Q J Nucl Med (ISSN: 1124-3937, 1125-0135), 1996; 40(4): 365-371.
Impact Factor: 2.125
View Export to BibTeX Export to EndNote
Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M, Muto P, Bernardy JD, Salvatore M
Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors (336 views)
Q J Nucl Med (ISSN: 1125-0135, 1124-3937), 1995 Dec; 39(4Suppl1): 145-149.
Impact Factor: 2.125
View Export to BibTeX Export to EndNote
Maurea S, Lastoria S, Cuocolo A, Celentano L, Salvatore M
The diagnosis of nonfunctioning pheochromocytoma the role of I-123 MIBG imaging (244 views)
Clin Nucl Med (ISSN: 0363-9762, 1536-0229, 1536-0229electronic), 1995 Jan; 20(1): 22-24.
Impact Factor: 0.34
View Export to BibTeX Export to EndNote
Lastoria S, Caraco C, Maurea S, Piroli C, Maurelli L, Vergara E, Klain M, Cuocolo A, Salvatore M
Evaluation of orbital involvement by neuroblastoma using radiolabeled metaiodobenzylguanidine (257 views)
Ital J Ophthalmol (ISSN: 0394-610x), 1993; 7(3): 147-152.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Maurea S, Cuocolo A, Reynolds JC, Choyke PL, Keiser HR, Neumann RD, Salvatore M
Role of magnetic resonance in the study of benign and malignant pheochromocytomas. Quantitative analysis of the intensity of the resonance signal (251 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 1993; 85(6): 803-808.
Impact Factor: 0.967
View Export to BibTeX Export to EndNote
Maurea S, Maurelli L, Lastoria S, Cuocolo A, Brunetti A, Pace L, Caracò C, Klain M, Lupoli G, Salvatore M
Familial pheochromocytoma in Sipple's syndrome. A comparison between scintigraphy with 131I-meta-iodobenzylguanidine, computed tomography and echography (251 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 1992; 83(4): 486-490.
Impact Factor: 0.967
View Export to BibTeX Export to EndNote
Maurelli L, Cuocolo A, Lastoria S, Brunetti A, Maurea S, Lembo G, Klain M, Carac C, Salvatore M
131I-meta-iodobenzylguanidine scintigraphy in patients with a suspected pheochromocytoma. A comparison with CT and biohumoral parameters (442 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 1991; 82(6): 839-843.
Impact Factor: 0.967
View Export to BibTeX Export to EndNote
* Pancreatic Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: Diagnostic Value of Different MRI Sequences (19 views)
Neuroendocrinology (ISSN: 0028-3835linking), 2021; 111(7): 696-704.
Impact Factor: 4.271
View Export to BibTeX Export to EndNote
Dell'Aversana S, Coppola M, Balestrieri U, Mainenti PP, Pascale C, Imbriaco M, Chianca V, Romeo V, Pellegrino T, Mainolfi C, Maurea S
* Integrated Imaging Characterization of Adrenal Adenoma: False-Positive Metaiodobenzylguanidine (MIBG) Findings of Adrenal Scintigraphy (167 views)
Pol J Radiol (ISSN: 1733-134xlinking), 2017 Aug 4; 82: 422-425.
Impact Factor: 0.567
View Export to BibTeX Export to EndNote
Lastoria S, Marciello F, Faggiano A, Aloj L, Caraco C, Aurilio M, D'Ambrosio L, Di Gennaro F, Ramundo V, Camera L, De LucaL, Fonti R, Napolitano V, Colao A
* Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1) (259 views)
Endocrine (ISSN: 1355-008x), 2016 Jun; 52(3): 488-494.
Impact Factor: 3.131
View Export to BibTeX Export to EndNote
Marcucci G, Cianferotti L, Beck-Peccoz P, Capezzone M, Cetani F, Colao A, Davì MV, Degli Uberti E, Del Prato S, Elisei R, Faggiano A, Ferone D, Foresta C, Fugazzola L, Ghigo E, Giacchetti G, Giorgino F, Lenzi A, Malandrino P, Mannelli M, Marcocci C, Masi L, Pacini F, Opocher G, Radicioni A, Tonacchera M, Vigneri R, Zatelli MC, Brandi ML
* Rare diseases in clinical endocrinology: A taxonomic classification system (778 views)
J Endocrinol Invest (ISSN: 1720-8386, 0391-4097, 1720-8386electronic), 2015; 38(2): 193-259.
Impact Factor: 1.994
View Export to BibTeX Export to EndNote
Maurea S, Fiumara G, Pellegrino T, Zampella E, Assante R, Mainenti PP, Cuocolo A
* MIBG molecular imaging for evaluating response to chemotherapy in patients with malignant pheochromocytoma: preliminary results (252 views)
Cancer Imaging (ISSN: 1470-7330, 1470-7330electronic, 1470-7330linking), 2013 Apr 15; 13: 155-161.
Impact Factor: 1.286
View Export to BibTeX Export to EndNote
De Luca S, Fonti R, Palmieri G, Federico P, Del Prete G, Pacelli R, Pace L, De Placido S, Salvatore M, Del Vecchio S
* Combined Imaging With 18f-Fdg-Pet/Ct And 111in-Labeled Octreotide Spect For Evaluation Of Thymic Epithelial Tumors (350 views)
Clin Nucl Med (ISSN: 1536-0229, 0363-3976, 0363-9762), 2013; 38(5): 354-358.
Impact Factor: 2.857
View Export to BibTeX Export to EndNote
Maurea S, Cuocolo A, Imbriaco M, Pellegrino T, Fusari M, Cuocolo R, Liuzzi R, Salvatore M
* Imaging characterization of benign and malignant pheochromocytoma or paraganglioma: comparison between MIBG uptake and MR signal intensity ratio (372 views)
Ann Nucl Med (ISSN: 1864-6433, 0914-7187, 1864-6433electronic), 2012 Oct; 26(8): 670-675.
Impact Factor: 1.41
View Export to BibTeX Export to EndNote
Faggiano A, Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Lombardi G, Colao A
* Long-Acting Somatostatin Analogues are Highly Effective in Patients with Early Stage MEN-1-Related Well-Differentiated Neuroendocrine Tumors (223 views)
Neuroendocrinology (ISSN: 0028-3835, 0028-3835linking), 2012; 96: N/D-N/D.
Impact Factor: 3.537
View Export to BibTeX Export to EndNote
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (479 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
View Export to BibTeX Export to EndNote
Maurea S, Soricelli A, Salvatore M
* Characterization of hypersecreting or non-hypersecreting adrenal adenomas: Comparison between iodine-131 nor-cholesterol scintigraphy and magnetic resonance imaging (315 views) (PDF 247 views)
Curr Radiopharm (ISSN: 1874-4710, 1874-4729), 2009; 2(1): 56-62.
Impact Factor: 0.643
View Export to BibTeX Export to EndNote
Maurea S, Imbriaco M, D'Angelillo M, Mollica C, Camera L, Salvatore M
* Diagnostic accuracy of chemical-shift MR imaging to differentiate between adrenal adenomas and non adenoma adrenal lesions (327 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 2006 Sep; 111(5): 674-686.
Impact Factor: 1.368
View Export to BibTeX Export to EndNote
Aloj L, Caracò C, Panico M, Zannetti A, Del Vecchio S, Tesauro D, De Luca S, Arra C, Pedone C, Morelli G, Salvatore M
* In vitro and in vivo evaluation of In-111-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging (587 views)
J Nucl Med (ISSN: 1535-5667, 0161-5505, 1535-5667electronic), 2004 Mar; 45(3): 485-494.
Impact Factor: 5.362
View Export to BibTeX Export to EndNote
Aloj L, Panico M, Caraco C, Del Vecchio S, Arra C, Affuso A, Accardo A, Mansi R, Tesauro D, De Luca S, Pedone C, Visentin R, Mazzi U, Morelli G, Salvatore M
* In vitro and in vivo characterization of Indium-111 and Technetium-99m labeled CCK-8 derivatives for CCK-B receptor imaging (519 views)
Cancer Biotherapy And Radiopharmaceuticals (ISSN: 1084-9785, 1084-4978), 2004 Feb; 19(1): 93-98.
Impact Factor: 1.091
View Export to BibTeX Export to EndNote
Maurea S, Caracò C, Klain M, Mainolfi C, Salvatore M
* Imaging characterization of non-hypersecreting adrenal masses. Comparison between MR and radionuclide techniques (350 views) (PDF 247 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2004; 48(3): 188-197.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
Camera L, Del Vecchio S, Quarantelli M, Ibello F, Pellegrino T, Salvatore M
* Radiolabeled somatostatin analogs in the diagnosis and staging of neuroendocrine tumors (329 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2003; 26(8Suppl): 60-62.
Impact Factor: 1.621
View Export to BibTeX Export to EndNote
Camera L, Biondi B, Daniele S, Pace L, Di Nuzzo L, Tortora F, Pulcrano M, Pagano L, Briganti F, Lombardi G, Salvatore M
* Screening in von Hippel-Lindau disease: Concurrent pheochromocytomas, paragangliomas and spinal hemangioblastomas revealed by helical-CT, MIBG scintigraphy and MRI in an asymptomatic patient (307 views)
Eur J Radiol Extra, 2003; 48(1): 8-13.
Impact Factor: 2.16
View Export to BibTeX Export to EndNote
Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M
* The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses (269 views) (PDF 247 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2001 Jun; 42(6): 884-892.
Impact Factor: 4.51
View Export to BibTeX Export to EndNote
Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G
The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas (387 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 1999 Mar; 22(3): 176-183.
Impact Factor: 0.957
View Export to BibTeX Export to EndNote
Lastoria S, Vergara E, Palmieri G, Acampa W, Varrella P, Caracò C, Bianco RA, Muto P, Salvatore M
In vivo detection of malignant thymic masses by indium-111-DTPA-D- Phe1-octreotide scintigraphy (428 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1998 Apr; 39(4): 634-639.
Impact Factor: 3.064
View Export to BibTeX Export to EndNote
Maurea S, Lastoria S, Caracò C, Klain M, Varrella P, Acampa W, Muto P, Salvatore M
The role of radiolabeled somatostatin analogs in adrenal imaging (358 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1996 Sep; 23(6): 677-680.
Impact Factor: 1.042
View Export to BibTeX Export to EndNote
Maurea S, Cuocolo A, Reynolds JC, Neumann RD, Salvatore M
Diagnostic imaging in patients with paragangliomas. Computer tomography, magnetic resonance and MIBG scintigraphy comparison (309 views)
Q J Nucl Med (ISSN: 1124-3937, 1125-0135), 1996; 40(4): 365-371.
Impact Factor: 2.125
View Export to BibTeX Export to EndNote
Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M, Muto P, Bernardy JD, Salvatore M
Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors (336 views)
Q J Nucl Med (ISSN: 1125-0135, 1124-3937), 1995 Dec; 39(4Suppl1): 145-149.
Impact Factor: 2.125
View Export to BibTeX Export to EndNote
Maurea S, Lastoria S, Cuocolo A, Celentano L, Salvatore M
The diagnosis of nonfunctioning pheochromocytoma the role of I-123 MIBG imaging (244 views)
Clin Nucl Med (ISSN: 0363-9762, 1536-0229, 1536-0229electronic), 1995 Jan; 20(1): 22-24.
Impact Factor: 0.34
View Export to BibTeX Export to EndNote
Lastoria S, Caraco C, Maurea S, Piroli C, Maurelli L, Vergara E, Klain M, Cuocolo A, Salvatore M
Evaluation of orbital involvement by neuroblastoma using radiolabeled metaiodobenzylguanidine (257 views)
Ital J Ophthalmol (ISSN: 0394-610x), 1993; 7(3): 147-152.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Maurea S, Cuocolo A, Reynolds JC, Choyke PL, Keiser HR, Neumann RD, Salvatore M
Role of magnetic resonance in the study of benign and malignant pheochromocytomas. Quantitative analysis of the intensity of the resonance signal (251 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 1993; 85(6): 803-808.
Impact Factor: 0.967
View Export to BibTeX Export to EndNote
Maurea S, Maurelli L, Lastoria S, Cuocolo A, Brunetti A, Pace L, Caracò C, Klain M, Lupoli G, Salvatore M
Familial pheochromocytoma in Sipple's syndrome. A comparison between scintigraphy with 131I-meta-iodobenzylguanidine, computed tomography and echography (251 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 1992; 83(4): 486-490.
Impact Factor: 0.967
View Export to BibTeX Export to EndNote
Maurelli L, Cuocolo A, Lastoria S, Brunetti A, Maurea S, Lembo G, Klain M, Carac C, Salvatore M
131I-meta-iodobenzylguanidine scintigraphy in patients with a suspected pheochromocytoma. A comparison with CT and biohumoral parameters (442 views)
Radiol Med (ISSN: 0033-8362, 1826-6983, 1826-6983electronic), 1991; 82(6): 839-843.
Impact Factor: 0.967
View Export to BibTeX Export to EndNote
27 Records (26 excluding Abstracts).
Total impact factor: 55.122 (51.585 excluding Abstracts).
Total 5 year impact factor: 64.724 (61.096 excluding Abstracts).
Total impact factor: 55.122 (51.585 excluding Abstracts).
Total 5 year impact factor: 64.724 (61.096 excluding Abstracts).
359 views. Last view on Sunday 19 March 2023, 9:53:17
ibb.cnr.it
